IMR Press / RCM / Volume 16 / Issue 2 / DOI: 10.3909/ricm0736

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
Natriuretic Peptides and the Management of Heart Failure
Show Less
1 David Geffen School of Medicine at UCLA, Los Angeles, CA
2 Cedars-Sinai Heart Institute, Los Angeles, CA
Rev. Cardiovasc. Med. 2015, 16(2), 95–104; https://doi.org/10.3909/ricm0736
Published: 30 June 2015
Abstract
Natriuretic peptide has been validated as a useful biomarker in the diagnosis of heart failure, although its role in guiding medical management of heart failure is not well established. We endeavored to determine if natriuretic peptide–guided therapy is associated with improved outcomes for heart failure patients. A total of 11 trials (2628 patients) comparing natriuretic peptide–guided therapy with standard therapy for heart failure patients were identified; follow-up times ranged from 3 months to 3 years. Our data indicate that natriuretic peptide levels and all-cause mortality rates do not appear to benefit from natriuretic peptide–guided therapy when compared with standard therapy. However, a decreased rate of cardiovascular events does appear to be associated with natriuretic peptide–guided therapy.
Keywords
Heart failure
Natriuretic peptide
Guided therapy
BNP
NT-proBNP
Share
Back to top